Advertisement

Pharmaceutical Chemistry Journal

, Volume 47, Issue 8, pp 399–404 | Cite as

5-HT3 Receptors as Targets for Biologically Active Compounds (Review)

  • A. A. Spasov
  • D. S. Yakovlev
MOLECULAR BIOLOGY PROBLEMS OF DRUG DESIGN AND MECHANISM OF DRUG ACTION

Subtype 3 serotonin receptors (5-HT3 receptors) are members of the cis-loop ligand-dependent ion channel family and have been studied intensely during the last 40 years. The structure of the main prototype, i.e., the homomeric 3A receptor, has now been determined; evidence of the existence and functional activity of heteromeric versions has been obtained. A multitude of ligands of 5-HT3 receptors has been studied and described, and these investigations continue as these compounds have great pharmaceutical potential. Along with the current use of 5-HT3 antagonists in a number of pathological states, including nausea and vomiting of various etiologies and irritable bowel syndrome, the evidence base for the potential of these compounds for other indications is growing quickly, especially in relation to anxiolytic, antipsychotic, and analgesic effects, as well as for the effective correction of alcohol addiction and inflammatory reactions. This review provides a brief description of the structural-functional characteristics of 5-HT3 receptors and their ligands, and the most important potentials for their use in clinical and experimental pharmacology are discussed.

Keywords

5-HT3 receptors serotonin 5-HT3 ligands 5-HT3 antagonists 

References

  1. 1.
    L. Färber, U. Haus, M. Späth, et al., Scand. J. Rheumatol., 119, 2 – 8 (2004).CrossRefGoogle Scholar
  2. 2.
    B. Niesler, J. Kapeller, C. Hammer, et al., Pharmacogenomics, 9(5), 501 – 504 (2008).PubMedCrossRefGoogle Scholar
  3. 3.
    N. P. Barrera, P. Herbert, R. M. Henderson, et al., Proc. Natl. Acad. Sci. USA, 102(35), 12,595 – 12,600 (2005).CrossRefGoogle Scholar
  4. 4.
    B. Niesler, Curr. Opin. Pharmacol., 11(1), 81 – 86 (2011).PubMedCrossRefGoogle Scholar
  5. 5.
    J. Kapeller, D. Müller, F. Lasitschka, et al., J. Comp. Neurol., 519(3), 420 – 432 (2011).PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    A. Keramidas, A. J. Moorhouse, P. R. Schofield, et al., Prog. Biophys. Mol. Biol., 86, 161 – 204 (2004).PubMedCrossRefGoogle Scholar
  7. 7.
    A. V. Popinako, Komp’yut. Issled. Model., 3(3), 329 – 334 (2011).Google Scholar
  8. 8.
    S. A. Monk, J. M. Williams, A. G. Hope, et al., Biochem. Pharmacol., 68(9), 1787 – 1796 (2004).PubMedCrossRefGoogle Scholar
  9. 9.
    M. R. Livesey, M. A. Cooper, T. Z. Deeb, et al., J. Biol. Chem., 283(28), 19,301 – 19,313 (2008).CrossRefGoogle Scholar
  10. 10.
    P. Chameau and J. A. van Hooft, Cell Tissue Res., 326(2), 573 – 581 (2006).PubMedCrossRefGoogle Scholar
  11. 11.
    M. C. Miquel, M. B. Emerit, A. Nosjean, et al., Eur. J. Neurosci., 15, 449 – 457 (2002).PubMedCrossRefGoogle Scholar
  12. 12.
    L. H. Tecott, A. V. Maricq, and D. Julius, Proc. Natl. Acad. Sci. USA, 90, 1430 – 1434 (1993).PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    S. L. Kitson, Curr. Pharm. Des., 13(25), 2621 – 2637 (2007). PubMedCrossRefGoogle Scholar
  14. 14.
    S. Katsurabayashi, H. Kubota, N. Tokutomi, et al., Neuropharmacology, 44, 1022 – 1030 (2003).PubMedCrossRefGoogle Scholar
  15. 15.
    S. Bradesi, L. Lao, P. McLean, et al., Pain, 130(1 – 2), 56 – 65 (2007).PubMedCrossRefGoogle Scholar
  16. 16.
    A. Harrell and A. Allan, Learn. Mem., 10(5), 410 – 419 (2003).PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Y. Levkovitz, G. Arnest, S. Mendlovic, et al., Brain Res. Bull., 65(4), 291 – 295 (2005).PubMedCrossRefGoogle Scholar
  18. 18.
    Yu. E. Trofimova, V. M. Smirnov, D. S. Sveshnikov, et al., Tekhnol. Zhiv. Sistem., 8(6), 69 – 73 (2011).Google Scholar
  19. 19.
    M. Hansen and A.Witte, Acta Physiol. (Oxf.), 193(4), 311 – 323 (2008).CrossRefGoogle Scholar
  20. 20.
    W. Müller and T. Stratz, Scand. J. Rheumatol., 33(119), 44 – 48 (2004).CrossRefGoogle Scholar
  21. 21.
    N. Chetty, H. Irving, and I. Coupar, Pharmacology, 81(2), 104 – 109 (2008).PubMedCrossRefGoogle Scholar
  22. 22.
    M. Dukat, R. Glennon, and S. Young, CNS Drug Rev., 13(1), 1 – 20 (2007).PubMedCrossRefGoogle Scholar
  23. 23.
    M.Wittmann, I. Peters, T. Schaaf, et al., Anesth. Analg., 103(3), 747 – 752 (2006).PubMedCrossRefGoogle Scholar
  24. 24.
    H. Nakayama, H. Yamakuni, M. Higaki, et al., J. Pharmacol. Sci., 98, 396 – 403 (2005).PubMedCrossRefGoogle Scholar
  25. 25.
    T. Yoshikawa, N. Yoshida, and M. Oka, Br. J. Pharmacol., 133, 253 – 260 (2001).PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    R. Manesh, R. V. Perumal, and P. V. Pandi, Biol. Pharm. Bull., 27(9), 1403 – 1405 (2004).CrossRefGoogle Scholar
  27. 27.
    Z. Yang, D. J. Fairfax, J. H. Maeng, et al., Bioorg. Med. Chem. Lett., 20(22), 6538 – 6541 (2010).PubMedCrossRefGoogle Scholar
  28. 28.
    O. N. Zefirova and N. S. Zefirov, Usp. Khim., 70(4), 382 – 407 (2001).Google Scholar
  29. 29.
    K. F. Suzdalev, A. A. Spasov, D. S. Yakovlev, et al., Khim.-Farm. Zh., 47(3), 3 – 7 (2013).Google Scholar
  30. 30.
    A. A. Spasov, D. S. Yakovlev, K. F. Suzdalev, et al., Pharm. Chem. J., 46(10), 584 – 590 (2013).CrossRefGoogle Scholar
  31. 31.
    O. N. Zefirova, T. Yu. Baranova, K. A. Lyssenko, et al., Mendeleev Commun., 22(2), 75 – 77 (2012).CrossRefGoogle Scholar
  32. 32.
    A. A. Spasov, M. V. Chernikov, D. S. Yakovlev, et al., Pharm. Chem. J., 40(11), 603 – 606 (2006).CrossRefGoogle Scholar
  33. 33.
    V. A. Anisimova, I. E. Tolpygin, A. A. Spasov, et al., Pharm. Chem. J., 40(6), 325 – 330 (2012).CrossRefGoogle Scholar
  34. 34.
    Russian Federation Patent 2438669; Byull. Izobret., No. 1 (2012).Google Scholar
  35. 35.
    D. S. Yakovlev, Author’s Abstract of Master’s Thesis in Medical Sciences, Volgograd (2007).Google Scholar
  36. 36.
    V. A. Anisimova, A. A. Spasov, I. E. Tolpygin, et al., Pharm. Chem. J., 44(7), 345 – 351 (2010).CrossRefGoogle Scholar
  37. 37.
    V. A. Anisimova, A. A. Spasov, I. E. Tolpygin, et al., Pharm. Chem. J., 44(5), 241 – 244 (2010).CrossRefGoogle Scholar
  38. 38.
    A. V. Ivashchenko, O. D. Mit’kin, V. M. Kisil’, et al., Khim.-Farm. Zh., 47(1), 13 – 20 (2013).Google Scholar
  39. 39.
    V. A. Anisimova, A. A. Spasov, V. A. Kosolapov, et al., Khim.-Farm. Zh., 46(9), 6 – 10 (2012).Google Scholar
  40. 40.
    Russian Federation Patent 2465901, Byull. Izobret., No. 31 (2012).Google Scholar
  41. 41.
    A. V. Ivashchenko, E. S. Golovina, M. G. Kadieva, et al., Khim.-Farm. Zh., 46(5), 14 – 24 (2012).Google Scholar
  42. 42.
    A. V. Ivashchenko, E. S. Golovina, M. G. Kadieva, et al., Khim.-Farm. Zh., 46(6), 14 – 22 (2012).Google Scholar
  43. 43.
    A. V. Ivashchenko, E. S. Golovina, M. G. Kadieva, et al., Khim.-Farm. Zh., 46(7), 19 – 23 (2012).Google Scholar
  44. 44.
    R. Gralla, M. Lichinitser, S. Van Der Vegt, et al., Ann. Oncol., 14(10), 1570 – 1577 (2003).PubMedCrossRefGoogle Scholar
  45. 45.
    A. Del Giglio, H. Soares, C. Caparroz, et al., Cancer, 89, 2301 – 2308 (2000).PubMedCrossRefGoogle Scholar
  46. 46.
    C. Craver, J. Gayle, S. Balu, et al., Med, Econ., 14(3), 341 – 349 (2011).CrossRefGoogle Scholar
  47. 47.
    H. T. Hatoum, S. J. Lin, D. Buchner, Support Care Cancer, 20(5), 941 – 949 (2011).PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    V. I. Legeza, A. B. Seleznev, and I. S. Drachev, Medical-Biological and Social-Psychological Problems of Safety in Emergency Situations [in Russian], No. 2, pp. 93 – 97 (2011).Google Scholar
  49. 49.
    R. C. Spiller, Curr. Opin. Pharmacol., 11(1), 68 – 74 (2011).PubMedCrossRefGoogle Scholar
  50. 50.
    T. Hirata, T. Funatsu, Y. Keto, et al., J. Pharmacol. Sci., 106, 264 – 270 (2008).PubMedCrossRefGoogle Scholar
  51. 51.
    A. C. Ford, L. J. Brandt, C. Young, et al., Am. J. Gastroenterol., 104(7), 1831 – 1843 (2009).PubMedCrossRefGoogle Scholar
  52. 52.
    Z. M. Ding, S. M. Oster, S. R. Hall, et al., Psychopharmacology (Berlin), 216(2), 245 – 255 (2011).CrossRefGoogle Scholar
  53. 53.
    Z. M. Ding, S. M. Oster, S. R. Hauser, et al., J. Pharmacol. Exp. Ther., 340(1), 202 – 209 (2012).PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    W. J. Lynch, C. Bond, F. J. Breslin, et al., Psychopharmacology (Berlin), 217(1), 3 – 12 (2011).CrossRefGoogle Scholar
  55. 55.
    Z. Song, B. A. Meyerson, B. Linderoth, Pain, 152(7), 1666 – 1673 (2011).PubMedCrossRefGoogle Scholar
  56. 56.
    M. Späth, T. Stratz, G. Neeck, et al., Scand. J. Rheumatol., 33(4), 267 – 270 (2004).PubMedCrossRefGoogle Scholar
  57. 57.
    P. Vergne-Salle, C. Dufauret-Lombard, C. Bonnet, et al., Eur. J. Pain, 15(5), 509 – 514 (2011).PubMedCrossRefGoogle Scholar
  58. 58.
    T. Stratz and W. Muller, Schmerz, 17(3), 200 – 203 (2003).PubMedGoogle Scholar
  59. 59.
    M. D. Crowell, Am. J. Manag. Care., No. 7, 252 – 260 (2001).Google Scholar
  60. 60.
    H. Zahedi, A. Maleki, and G. Rostami, Acta. Med. Iran., 50(4), 239 – 243 (2012).PubMedGoogle Scholar
  61. 61.
    S. Bhamagar, N. Nowak, L. Babich, et al., Behav. Brain Res., 153, 527 – 535 (2004).CrossRefGoogle Scholar
  62. 62.
    S. P. Kelley, A. M. Bratt, and C. W. Hodge, Eur. J. Pharmacol., 461, 19 – 25 (2003).PubMedCrossRefGoogle Scholar
  63. 63.
    B. Kumar, A. Jindal, D. K. Pandey, et al., Indian J. Exp. Biol., 50(9), 625 – 632 (2012).PubMedGoogle Scholar
  64. 64.
    M. V. Chernikov, A. A. Spasov, and V. A. Anisimova, Eur. Neuropsychopharmacol., 15, Supplement 2, 147 – 148 (2005).CrossRefGoogle Scholar
  65. 65.
    D. Yakovlev, N. Kolobrodova, A. Spasov, et al., Eur. Neuropsychopharmacol., 21, Supplement 2, 147 (2011).CrossRefGoogle Scholar
  66. 66.
    N. Askari, M. Moin, M. Sanati, et al., CNS Drugs, 26(10), 883 – 892 (2012).PubMedCrossRefGoogle Scholar
  67. 67.
    E. Nowakowska, A. Chodera, and K. Kus, Pharmacol. Biochem. Behav., 59(4), 935 – 938 (1998).PubMedCrossRefGoogle Scholar
  68. 68.
    D. S. Yakovlev, N. A. Kolobrodova, A. A. Spasov, et al., in: Proceedings of the 17th Multidisciplinary International Conference on Neuroscience and Biological Psychiatry “Stress and Behavior”, St. Petersburg (2012), pp. 22 – 23.Google Scholar
  69. 69.
    T. Hoşten, M. Solak, L. Elemen, et al., Anaesth. Intensive Care, 39(4), 640 – 645 (2011).PubMedGoogle Scholar
  70. 70.
    S. Akhondzadeh, N. Mohammadi, M. Noroozian, et al., Schizophr. Res., 107(2 – 3), 206 – 212 (2009).PubMedCrossRefGoogle Scholar
  71. 71.
    M. R. Khodaie-Ardakani, S. Seddighi, A. Modabbernia, et al., J. Psychiatr. Res., 47(4), 472 – 478 (2013).PubMedCrossRefGoogle Scholar
  72. 72.
    N. Maleki-Dizaji, T. Eteraf-Oskouei, A. Fakhrjou, et al., Int. Immunopharmacol., 10(9), 1010 – 1016 (2010).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • A. A. Spasov
    • 1
  • D. S. Yakovlev
    • 1
  1. 1.Volgograd State Medical UniversityVolgogradRussia

Personalised recommendations